CTLA4 and melanoma: Tebentafusp, a bispecific protein immunotherapy targeting CD3 and melanoma-specific gp100, has also shown activity in early-phase clinical studies [21], and combined PD-1 and CTLA4 immune checkpoint inhibition appears to be more effective than monotherapy, albeit not as effective as in cutaneous melanoma [22].